RalA suppresses early stages of Ras-induced squamous cell carcinoma progression
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Ras proteins activate Raf and PI-3 kinases, as well as exchange factors for RalA and RalB GTPases. Many previous studies have reported that the Ral-signaling cascade contributes positively to Ras-mediated oncogenesis. Here, using a bioengineered tissue model of early steps in Ras-induced human squamous cell carcinoma of the skin, we found the opposite. Conversion of Ras-expressing keratinocytes from a premalignant to malignant state induced by decreasing E-cadherin function was associated with and required an approximately two to threefold decrease in RalA expression. Moreover, direct knockdown of RalA to a similar degree by shRNA expression in these cells reduced E-cadherin levels and also induced progression to a malignant phenotype. Knockdown of the Ral effector, Exo84, mimicked the effects of decreasing RalA levels in these engineered tissues. These phenomena can be explained by our finding that the stability of E-cadherin in Ras-expressing keratinocytes depends upon this RalA signaling cascade. These results imply that an important component of the early stages in squamous carcinoma progression may be a modest decrease in RalA gene expression that magnifies the effects of decreased E-cadherin expression by promoting its degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia
Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y., et al. (2003) · Nature · doi:10.1038/nature01283 · Cited by 535 · cited 1×
“A significant proportion of these cancers contain either mutations in Ras genes that lead to constitutively-activated Ras GTPases or amplified levels of Ras proteins (Dajee et al., 2003; Pierceall et al., 1991).”
BackgroundThe exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423 · cited 1×
“…four effector proteins, the RalBP-1 (Cantor et al., 1995; Jullien-Flores et al., 1995), the exocyst subunits Sec5 and Exo84 (Brymora et al., 2001; Moskalenko et al., 2002; Moskalenko et al., 2003; Polzin et al., 2002; Sugihara et al., 2002), and the transcription factor ZONAB (Frankel et al.,…”
BackgroundActivation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355 · cited 8×
“Many previous studies have indicated that Ral-GEFs, RalA and RalB play positive roles in transformation of cells containing an oncogenic form of Ras (Bodemann & White, 2008).”
BackgroundSelf-citationBridging Ral GTPase to Rho Pathways
Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., & Camonis, J. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22473 · Cited by 338
Cantor, S. B., Urano, T., & Feig, L. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4578 · Cited by 310
Self-citationThe exocyst complex binds the small GTPase RalA to mediate filopodia formation
Sugihara, K., Asano, S., Tanaka, K., Iwamatsu, A., Okawa, K., & Ohta, Y. (2002) · Nature Cell Biology · doi:10.1038/ncb720 · Cited by 258 · cited 1×
“…effector proteins, the RalBP-1 (Cantor et al., 1995; Jullien-Flores et al., 1995), the exocyst subunits Sec5 and Exo84 (Brymora et al., 2001; Moskalenko et al., 2002; Moskalenko et al., 2003; Polzin et al., 2002; Sugihara et al., 2002), and the transcription factor ZONAB (Frankel et al., 2005).”
BackgroundRal-GTPases: approaching their 15 minutes of fame.
Feig, L. A. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00152-1 · Cited by 249
Self-citationThe Brain Exocyst Complex Interacts with RalA in a GTP-dependent Manner
Brymora, A., Valova, V. A., Larsen, M. R., Roufogalis, B. D., & Robinson, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100320200 · Cited by 143 · cited 3×
“When activated, Ral proteins can bind to at least four effector proteins, the RalBP-1 (Cantor et al., 1995; Jullien-Flores et al., 1995), the exocyst subunits Sec5 and Exo84 (Brymora et al., 2001; Moskalenko et al., 2002; Moskalenko et al., 2003; Polzin et al., 2002; Sugihara et al., 2002), and the transcription facto…”
BackgroundRalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1957 · Cited by 139
Fenwick, R. B., Prasannan, S., Campbell, L. J., Nietlispach, D., Evetts, K. A., Camonis, J., Mott, H. R., & Owen, D. (2009) · Biochemistry · doi:10.1021/bi802129d · Cited by 47 · cited 1×
“Despite their ∼85% identity, RalA and RalB play very different roles in cells, presumably due to their distinct subcellular localization (Lim et al., 2005; Shipitsin & Feig, 2004) and differences in affinities for effectors (Fenwick et al., 2009; Shipitsin & Feig, 2004).”
Background
Cited by
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
“One exception, however, is squamous cell carcinoma (SCC), where RALA was found to suppress rather than promote tumor progression in SCC cancer cell lines (Sowalsky et al., 2010).”
BackgroundRal signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
“Ral activation was shown to be involved in a number of different tumor types such as lung [105], colorectal [108], melanoma [109, 110], pancreatic [111], squamous cell carcinoma [112], hepatocellular carcinoma [113, 114], prostate [115], ovarian [116], bladder [12], chronic myelogenous leukemia [117], peripheral nerve…”
BackgroundRal activation promotes melanomagenesis
Zipfel, P. A., Brady, D. C., Kashatus, D. F., Ancrile, B. D., Tyler, D. S., & Counter, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.224 · Cited by 47
“Nevertheless, similar to RalB, the requirement for RalA may still be context dependent, as it was recently reported that knockdown of RalA enhanced the tumorigenic growth of the HaCaT keratinocyte cell line transformed by ectopic oncogenic HRas (Sowalsky et al., 2009).”
InfluentialNeyraud, V., Aushev, V. N., Hatzoglou, A., Meunier, B., Cascone, I., & Camonis, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357764 · Cited by 28
Metadata
- Authors
- Sowalsky, A. G., Alt-Holland, A., Shamis, Y., Garlick, J. A., & Feig, L. A.
- Venue
- Oncogene
- Published
- 2009-10-05
- Volume
- 29
- Issue
- 1
- Pages
- 45-55
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2064212866
- Cited by
- 25
- References
- 10
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.